

**Reach** Non Regulatory Reach Announcement



## STRATEGIC TECHNOLOGY COLLABORATION

### [GENFLOW BIOSCIENCES PLC](#)

Released 07:00:08 20 April 2026

RNS Number : 0897B  
Genflow Biosciences PLC  
20 April 2026

### **Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform**

Genflow Biosciences Plc (LSE: GENF | OTCQB: GENFF) ("Genflow" or the "Company"), a European biotechnology company focused on the development of gene therapies for age-related diseases, today announces that it has entered into a strategic technology collaboration with Acuitas Therapeutics ("Acuitas"), a globally recognised leader in lipid nanoparticle ("LNP") delivery systems whose technology has underpinned some of the most commercially successful mRNA therapeutic programmes brought to market to date.

#### **Strategic Significance**

The Board considers this collaboration to represent a material step forward in the advancement of the Company's SIRT6 platform. Acuitas' LNP technology is among the most clinically and commercially validated delivery platforms in the mRNA therapeutics industry, and the Company's ability to access this capability on a fully funded basis reflects the external confidence in Genflow's proprietary science.

The collaboration will enable Genflow to evaluate the integration of LNP-based delivery with its SIRT6 mRNA payload across a newly initiated development programme, with the objective of generating preclinical data to support future clinical and commercial development decisions.

#### **Terms of the Collaboration**

Under the agreement, Genflow will provide its proprietary SIRT6 mRNA payload to Acuitas, which will formulate the payload using its proprietary LNP platform. The resulting formulations will be returned to Genflow for use in preclinical evaluation studies.

The collaboration is fully funded by Acuitas. There is no cash consideration payable by Genflow, and the arrangement is entirely non-dilutive to existing shareholders. The Company does not expect the collaboration to have a material impact on near-term revenues.

While the current agreement is focused on initial preclinical evaluation activities, it establishes a formal framework for potential further development and strategic engagement between the parties, subject to the outcome of the ongoing work.

#### **About Acuitas Therapeutics**

Acuitas is a privately held biopharmaceutical company headquartered in Vancouver, Canada, and is one of the foremost specialists in the development and licensing of LNP technology for mRNA-based therapeutics. Acuitas' LNP platform has been incorporated into multiple landmark mRNA programmes that have achieved both regulatory approval and large-scale commercial success, establishing Acuitas as a pre-eminent partner of choice for leading organisations advancing mRNA medicines globally.

The Board regards Acuitas' decision to invest its own resources in formulating Genflow's SIRT6 mRNA payload as a meaningful and independent validation of the quality and potential of the Company's proprietary technology.

### **Outlook and Commercial Potential**

The data generated through this collaboration are expected to inform key future development decisions, including delivery optimisation, target tissue engagement, and the structuring of potential partnering and licensing arrangements with third parties. The Company's SIRT6 platform addresses mechanisms of fundamental importance to age-related disease, and the addition of an optimised LNP delivery modality is expected to materially broaden the scope and commercial attractiveness of the programme.

The Company will provide further updates on the progress of this collaboration as developments warrant and in accordance with its obligations under the Market Abuse Regulation.

Eric Leire, Chief Executive Officer of Genflow Biosciences, commented:

*"This collaboration with Acuitas is, in our view, one of the most significant steps we have taken in the development of our SIRT6 platform to date. Acuitas are the gold standard in LNP delivery - their technology has already transformed modern medicine - and the fact that they are committing their own resources to work with our science is a powerful endorsement of what we are building. For our shareholders, the headline facts are straightforward: we are gaining access to world-class, clinically proven delivery technology at no cost and with no dilution. This is precisely the kind of capital-efficient, high-impact collaboration that de-risks our pipeline, strengthens our partnering position, and accelerates our path towards clinical development. We look forward to sharing further updates as this programme advances."*

### **Contacts**

Genflow Biosciences

Harbor Access

Dr Eric Leire, CEO

Jonathan Paterson, Investor Relations

+32 477495 881

+1 475 477 9401

Jonathan@Harbor-Access.com

### **About Genflow Biosciences**

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit [www.genflowbio.com](http://www.genflowbio.com) and follow the Company on [LinkedIn](#) and [X](#).

### **DISCLAIMER**

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).